Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Free Cash Flow (2017 - 2024)

Solid Biosciences' Free Cash Flow history spans 8 years, with the latest figure at -$29.2 million for Q4 2024.

  • For Q4 2024, Free Cash Flow fell 39.6% year-over-year to -$29.2 million; the TTM value through Dec 2024 reached -$100.0 million, down 4.51%, while the annual FY2024 figure was -$100.0 million, 4.51% down from the prior year.
  • Free Cash Flow for Q4 2024 was -$29.2 million at Solid Biosciences, down from -$24.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $1.2 million in Q4 2020 and bottomed at -$35.3 million in Q4 2022.
  • The 5-year median for Free Cash Flow is -$21.6 million (2021), against an average of -$21.7 million.
  • The largest annual shift saw Free Cash Flow skyrocketed 105.7% in 2020 before it crashed 1849.0% in 2021.
  • A 5-year view of Free Cash Flow shows it stood at $1.2 million in 2020, then plummeted by 1849.0% to -$21.8 million in 2021, then plummeted by 62.02% to -$35.3 million in 2022, then soared by 40.82% to -$20.9 million in 2023, then crashed by 39.6% to -$29.2 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Free Cash Flow are -$29.2 million (Q4 2024), -$24.1 million (Q3 2024), and -$21.5 million (Q2 2024).